We are seeing patients in-person and through Video Visits. Learn more about how we’re keeping you safe and please review our updated visitor policy. Please also consider supporting Weill Cornell Medicine’s efforts to support our front-line workers.

You are here

SERENADE/AC-055-G202 study - Macitentan in Heart Failure, A multi-center, double-blind, placebo-controlled Phase 2b study to evaluate the efficacy and safety of macitentan in subjects with heart failure with preserved ejection fraction and pulmonary vascular disease

IRB Protocol #: 1710018707 

Overview: There are several drugs available to manage heart failure symptoms, but to date, no treatments have been approved specifically for left heart failure with preserved ejection fraction and pulmonary vascular disease. The purpose of this study is to find out whether macitentan works and is safe in this disease.

This trial is funded by Actelion Pharmaceuticals Ltd.

Eligible patients must have:  

•          Left ventricular ejection fraction (LVEF) ≥ 40%

•          New York Heart Association (NYHA) functional class (FC) II to III


Patients cannot participate if they have:

•          Any prior measurement of LVEF < 40%

•          Known indication for PCI or CABG



Dr. Evelyn Horn
Principle Investigator
Email: horneve@med.cornell.edu
Phone: (212) 746-2381

Melissa Ricketts, MSHS, CCRC
Research Coordinator
Email: mdr2001@med.cornell.edu
Phone: (212) 746-2698

Make an Appointment

(646) 962-5558

Weill Cornell Medicine
Division of Cardiology

520 East 70th Street
Starr 443
New York, NY 10021

1305 York Avenue, 8th Floor
New York, NY 10021